Novo Nordisk will have to fulfill requests from the FDA regarding the manufacturing process and the indication before it can receive approval for insulin icodec.
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people irrespective of the amount of weight they lose while using the medication, according to a new study.
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, have garnered a lot of attention in the pharma industry and beyond.
Eli Lilly may be on the brink of reshaping the pharma landscape, with its treatments, Mounjaro (tirzepatide) for obesity and the highly anticipated donanemab for early symptomatic Alzheimer’s disease.
Specific doses of Eli Lilly’s GLP-1 blockbuster drugs Mounjaro and Zepbound are currently facing a supply shortage, and frustrated patients are urging the pharma giant to act – fast.
Pharma giant Novo Nordisk is firing back after Senator Bernie Sanders took a stand against the ‘outrageous’ prices of its wildly popular drugs, Ozempic and Wegovy.
Eli Lilly is partnering with ecommerce titan Amazon to deliver its weight loss drug Zepbound straight to patient’s doors, in a bid to address ongoing shortages.
The unprecedented demand for GLP-1 medicines, fuelled by their remarkable ability to help patients shed up to 20% of body weight, has been nothing short of explosive.
Swedish-based company Empros Pharma has announced positive topline data from its phase 2b trial investigating EMP16, an oral therapy for the treatment of obesity.
Novo Nordisk is set to acquire three manufacturing facilities from contract development and manufacturing organization Catalent, in a bold move that has sparked a great deal of debate and some backlash.
Novo Nordisk's Ozempic (semaglutide) took the weight loss sector by storm in 2023, propelled by strong efficacy and safety data, coupled with social media buzz and celebrity endorsements that elevated the drug to mainstream prominence.
The Novo Nordisk Foundation is planning to build a €127 million ($135 million) facility in Denmark to speed up the development and manufacturing process for cell therapies for use in early clinical trials.
Aspect Biosystems and Novo Nordisk have announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics to replace or repair biological functions in the body: with the aim of creating a ‘new class of truly disease-modifying...
Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational services, cloud, and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development, and data science capabilities.
Novo Nordisk has announced positive results from a Phase 3 study assessing the efficacy and safety of concizumab, its prophylactic treatment of hemophilia A or B with inhibitors.
Through funding by Novo Nordisk and the NIH, researchers from MIT have come up with a microneedle containing capsule able to release drug substance into the bloodstream.
Novo Nordisk partners with bluebird on a three-year research arrangement looking to discover gene therapy candidates for the treatment of genetic diseases, including hemophilia.
Novo Holdings invests £53.5m in Oxford Biomedica, funds which the company will use to further develop its LentiVector platform for cell and gene therapies.
This month’s round-up of the most popular stories of the month, featuring a bold prediction of future growth for Chinese biotech and bad news for a potential treatment for Alzheimer’s disease.
The Danish drugmaker announced that job losses at the company will number 1,300 before the end of the year, with the majority of those already having left their roles.
In a significant move at the larger end of the biopharma world, AstraZeneca’s global VP of cardiovascular, renal and metabolism made the move to Novo Nordisk to head up its biopharm unit.
Novo Nordisk will take over the lease of a manufacturing facility in Fremont, California, where the company will make stem cell-based therapies with optionally licensed technology.
Novo Nordisk has called on the board of directors at Ablynx to engage in negotiations after the antibody-fragment tech firm rejected its €2.6bn ($3.1bn) acquisition offer.
Novartis will continue investing in its manufacturing network to support a biologics pipeline which includes five new biosimilars it expects to launch by 2020.
